Literature DB >> 16503077

Staging systems for hepatocellular carcinoma: should we all use the BCLC system?

Jorge A Marrero.   

Abstract

Entities:  

Mesh：

Year:  2006        PMID： 16503077     DOI： 10.1016/j.jhep.2006.02.003

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  11 in total

1.  Surgical resection for advanced hepatocellular carcinoma according to Barcelona Clinic Liver Cancer (BCLC) staging.

Authors:  Tian Yang; Chuan Lin; Jian Zhai; Song Shi; Min Zhu; Nan Zhu; Jun-Hua Lu; Guang-Shun Yang; Meng-Chao Wu
Journal:  J Cancer Res Clin Oncol       Date:  2012-03-10       Impact factor: 4.553

2.  Are surgical indications of Barcelona Clinic Liver Cancer staging classification justified?

Authors:  Shuang Wei; Xiaoyi Hao; Daqian Zhan; Min Xiong; Kaiyan Li; Xiaoping Chen; Zhiyong Huang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-10-25

3.  Validation of the Hong Kong Liver Cancer Staging System in Determining Prognosis of the North American Patients Following Intra-arterial Therapy.

Authors:  Jae Ho Sohn; Rafael Duran; Yan Zhao; Florian Fleckenstein; Julius Chapiro; Sonia Sahu; Rüdiger E Schernthaner; Tianchen Qian; Howard Lee; Li Zhao; James Hamilton; Constantine Frangakis; MingDe Lin; Riad Salem; Jean-Francois Geschwind
Journal:  Clin Gastroenterol Hepatol       Date:  2016-11-12       Impact factor: 11.382

4.  Arterial blood supply of hepatocellular carcinoma is associated with efficacy of sorafenib therapy.

Authors:  Qian Zhu; Xianghua Zhang; Jing Li; Liang Huang; Jianjun Yan; Feng Xu; Yiqun Yan
Journal:  Ann Transl Med       Date:  2015-11

5.  Risk factors and surgical outcomes for spontaneous rupture of BCLC stages A and B hepatocellular carcinoma: a case-control study.

Authors:  Jing Li; Liang Huang; Cai-Feng Liu; Jie Cao; Jian-Jun Yan; Feng Xu; Meng-Chao Wu; Yi-Qun Yan
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

Review 6.  Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps.

Authors:  Augusto Villanueva; Sara Toffanin; Josep M Llovet
Journal:  Curr Opin Oncol       Date:  2008-07       Impact factor: 3.645

7.  Maximum predictive power of the microarray-based models for clinical outcomes is limited by correlation between endpoint and gene expression profile.

Authors:  Chen Zhao; Leming Shi; Weida Tong; John D Shaughnessy; André Oberthuer; Lajos Pusztai; Youping Deng; W Fraser Symmans; Tieliu Shi
Journal:  BMC Genomics       Date:  2011-12-23       Impact factor: 3.969

8.  Metabolic Reprogramming and Risk Stratification of Hepatocellular Carcinoma Studied by Using Gas Chromatography-Mass Spectrometry-Based Metabolomics.

Authors:  Chengnan Fang; Hui Wang; Zhikun Lin; Xinyu Liu; Liwei Dong; Tianyi Jiang; Yexiong Tan; Zhen Ning; Yaorui Ye; Guang Tan; Guowang Xu
Journal:  Cancers (Basel)       Date:  2022-01-04       Impact factor: 6.639

9.  An atypical age-specific pattern of hepatocellular carcinoma in Peru: a threat for Andean populations.

Authors:  Stéphane Bertani; Pascal Pineau; Sebastian Loli; Julien Moura; Mirko Zimic; Eric Deharo; Eloy Ruiz
Journal:  PLoS One       Date:  2013-06-28       Impact factor: 3.240

10.  Early and very early hepatocellular carcinoma: when and how much do staging and choice of treatment really matter? A multi-center study.

Authors:  Fabio Farinati; Adriana Sergio; Anna Baldan; Anna Giacomin; Maria Anna Di Nolfo; Paolo Del Poggio; Luisa Benvegnu; Gianludovico Rapaccini; Marco Zoli; Franco Borzio; Edoardo G Giannini; Eugenio Caturelli; Franco Trevisani
Journal:  BMC Cancer       Date:  2009-01-27       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.